ERNA - Eterna Therapeutics Inc.

0.1907
-0.003   -1.783%

Share volume: 290,733
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$0.19
0.00
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
43%
Profitability 35%
Dept financing 40%
Liquidity 46%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-8.23%
1 Month
-18.85%
3 Months
-84.62%
6 Months
-83.42%
1 Year
3.53%
2 Year
-35.36%
Key data
Stock price
$0.19
P/E Ratio 
N/A
DAY RANGE
$0.19 - $0.20
EPS 
-$1.15
52 WEEK RANGE
$0.14 - $2.86
52 WEEK CHANGE
-$1.60
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
29.154 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-29-2025
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$1,270,543
AVERAGE 30 VOLUME 
$850,477
Company detail
CEO: Matthew Angel
Region: US
Website: brooklynitx.com
Employees: 10
IPO year: 2006
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Brooklyn ImmunoTherapeutics, Inc. engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology.

Recent news